Rogers Commun CL B (RG) News

Helix Exploration PLC CEO Bo Sears talked with Proactive's Stephen Gunnion about the company’s development progress at its Rudyard project in Montana. Sears said the company is “progressing nicely” with the Linda #1 well and is on track to begin producing helium by the end of summer. He pointed to strong early results from both Darwin #1 and the acquisition of the Weil #1 well, expressing optimism about long-term production capacity. He described Rudyard as “quite large relative to our peers,” adding that it may support up to 20 wells—substantially more than originally anticipated. This scale opens the potential for on-site helium liquefaction, with HeLIX already acquiring 20 acres in preparation. Sears referenced a 1977 US Bureau of Mines study that estimated the field's potential at 2.60 billion cubic feet of helium. With new drilling data, including from Linda #1 and re-perforated Weil #1, the company expects to significantly update resource estimates. The company anticipates up to 4 billion cubic feet of recoverable helium, which Sears noted could make Helix one of the largest helium producers in the US. Sears also confirmed ongoing discussions with off-takers and potential interest in geological hydrogen from deeper zones. Visit Proactive’s YouTube channel for more interviews. Don’t forget to like this video, subscribe to the channel, and enable notifications for future updates. #HeLIXExploration #HeliumProduction #NaturalGas #RudyardField #BoSears #MontanaEnergy #EnergyExploration #HydrogenExploration #ProactiveInvestors #USHeliumMarket

EnWave Corporation CEO Brent Charleton joined Steve Darling from Proactive to announce a significant expansion of the company’s long-standing relationship with MicroDried, its original royalty partner and a leader in premium fruit and vegetable ingredient production. The announcement includes the signing of an Equipment Purchase Agreement and License Amendment, under which MicroDried will acquire an additional 60kW Radiant Energy Vacuum (REV™) machine to increase production capacity in response to rising demand for its clean-label, nutrient-rich ingredients. MicroDried currently operates three large-scale REV™ dehydration lines at its facility in Nampa, Idaho. Charleton emphasized MicroDried’s extensive portfolio and deep integration with leading global consumer packaged goods (CPG) brands. In addition to the new equipment purchase, the license amendment grants MicroDried exclusive rights to produce apple-based ingredients using REV™ technology within Washington, Oregon, and Idaho—further entrenching its leadership in vertically integrated, value-added fruit processing. As part of the agreement, MicroDried also holds an option to purchase a second additional 60kW REV™ machine before July 31, 2025. Should that option be exercised, a pre-negotiated bulk discount will apply—an incentive that supports long-term production scalability. With demand for shelf-stable, nutritious ingredients continuing to rise across the global food industry, this expanded partnership underscores the value of EnWave’s proprietary dehydration technology and its ability to power efficient, high-quality production at scale. #proactiveinvestors #enwavecorporation #tsxv #enw #DehydrationTech #VacuumMicrowave #RoyaltyBusinessModel #BluechipClients #FoodTech #BusinessNews #Investing #CEOInterview #Peru #Spain #Blueberry #Snacks #Royalties #TradeMission

Ecora Resources PLC CEO Marc Bishop Lafleche takes Proactive's Stephen Gunnion through the company’s first quarter trading update and outlook for the rest of 2025. He described the start to the year as a “very solid” one, highlighting a portfolio contribution of $6 million, which notably excludes revenue from both Mimbula and Four Mile due to a reporting lag. Lafleche emphasised strong performance at Voisey’s Bay underground and the achievement of a second consecutive quarterly record at Mantos Blancos. A major development during the period was the $50 million acquisition of Mimbula, which Lafleche said marks a strategic milestone. He reiterated that Voisey’s Bay is on track for 60% to 90% volume growth following underground expansion, with full-year guidance between 335 to 390 tonnes, skewed towards the second half. Ecora is also seeing positive pricing momentum for cobalt, with April prices nearing $19 per pound**, up from $13 in Q1, following a DRC export ban. Looking ahead to Q2, the company expects the initial revenues from the dollar stream and normalisation of royalty income from Four Mile. Lafleche also noted the anticipated return of mining within the royalty area at Kestrel, leading to stronger volumes into Q3. For more updates from Ecora Resources and other listed companies, visit Proactive's YouTube channel. Don’t forget to like the video, subscribe to the channel, and enable notifications to stay informed. #EcoraResources #MiningUpdate #CobaltPrices #VoiseysBay #MimbulaAcquisition #Q12025Results #MiningStocks #RoyaltyIncome #KestrelMining #ProactiveInvestors

Arecor Therapeutics CEO Sarah Howell talked with Proactive's Stephen Gunnion about the company’s strong progress across its proprietary diabetes and obesity pipeline and partnerships. The discussion followed the release of Arecor Therapeutics’ full-year 2024 results, where Howell detailed advances in AT278 — a highly concentrated, ultra-rapid acting insulin shown to be effective in patients with Type 2 diabetes and high BMI. AT278, according to Howell, delivers faster insulin onset and superior glucose control compared to current market alternatives. “We got more insulin on board faster,” she said, highlighting the product’s pharmacokinetic and pharmacodynamic advantages. She added that the insulin is particularly suited for use in insulin pump therapies, especially for patients requiring high daily doses — a segment traditionally underserved by existing pump solutions. Beyond injectables, Arecor has entered the oral peptide delivery space with a new platform targeting enhanced bioavailability, initially focusing on oral GLP-1 for obesity. Howell noted, “We have overcome the first significant challenges of stabilising the peptide,” using the company’s Arestat technology, with semaglutide development underway to improve upon existing oral GLP-1 drugs like Rybelsus. The company continues to expand its partner network and revenue-generating collaborations. It expects key data from oral peptide studies and a potential strategic partnership announcement for AT278 during 2025. For more insightful updates from biotech and pharma leaders, visit Proactive’s YouTube channel. Don’t forget to like this video, subscribe, and enable notifications to stay updated! #ArecorTherapeutics #AT278 #InsulinPump #GLP1 #DiabetesTreatment #ObesityDrugs #BiotechNews #PharmaInnovation #Semaglutide #OralDelivery #DrugDevelopment #ProactiveInvestors